Main variables;No. of employees;Total
No. of companies carrying out R&D in Biotechnology;Fewer than 250 employees;1.040
No. of companies carrying out R&D in Biotechnology;250 or more employees;93
No. of companies carrying out R&D in Biotechnology;Total;1.133
%Companies according to biotechnology used: Genetic code;Fewer than 250 employees;32
%Companies according to biotechnology used: Genetic code;250 or more employees;43
%Companies according to biotechnology used: Genetic code;Total;33
%Companies according to biotechnology used: Functional units;Fewer than 250 employees;40
%Companies according to biotechnology used: Functional units;250 or more employees;51
%Companies according to biotechnology used: Functional units;Total;41
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Fewer than 250 employees;22
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;250 or more employees;41
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Total;24
%Companies according to biotechnology used: Bioprocesses;Fewer than 250 employees;48
%Companies according to biotechnology used: Bioprocesses;250 or more employees;69
%Companies according to biotechnology used: Bioprocesses;Total;50
%Companies according to biotechnology used: Sub-cellular organisms;Fewer than 250 employees;5
%Companies according to biotechnology used: Sub-cellular organisms;250 or more employees;12
%Companies according to biotechnology used: Sub-cellular organisms;Total;6
%Companies according to biotechnology used: Bio-computing;Fewer than 250 employees;24
%Companies according to biotechnology used: Bio-computing;250 or more employees;28
%Companies according to biotechnology used: Bio-computing;Total;24
%Companies according to biotechnology used: Nanobiotechnology;Fewer than 250 employees;13
%Companies according to biotechnology used: Nanobiotechnology;250 or more employees;13
%Companies according to biotechnology used: Nanobiotechnology;Total;13
%Companies according to biotechnology used: Other;Fewer than 250 employees;15
%Companies according to biotechnology used: Other;250 or more employees;8
%Companies according to biotechnology used: Other;Total;14
Companies in which biotechnology activities are: Main and/or exclusive;Fewer than 250 employees;581
Companies in which biotechnology activities are: Main and/or exclusive;250 or more employees;22
Companies in which biotechnology activities are: Main and/or exclusive;Total;603
Companies in which biotechnology activities are: A secondary line of business;Fewer than 250 employees;155
Companies in which biotechnology activities are: A secondary line of business;250 or more employees;18
Companies in which biotechnology activities are: A secondary line of business;Total;173
Companies in which biotechnology activities are: A tool necessary for production;Fewer than 250 employees;305
Companies in which biotechnology activities are: A tool necessary for production;250 or more employees;53
Companies in which biotechnology activities are: A tool necessary for production;Total;357
%Company by field(s) of ultimate application of biotechnology use: Human Health;Fewer than 250 employees;45
%Company by field(s) of ultimate application of biotechnology use: Human Health;250 or more employees;49
%Company by field(s) of ultimate application of biotechnology use: Human Health;Total;45
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Fewer than 250 employees;19
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;250 or more employees;3
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Total;18
%Company by field(s) of ultimate application of biotechnology use: Food products;Fewer than 250 employees;30
%Company by field(s) of ultimate application of biotechnology use: Food products;250 or more employees;39
%Company by field(s) of ultimate application of biotechnology use: Food products;Total;31
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Fewer than 250 employees;23
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;250 or more employees;17
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Total;22
%Company by field(s) of ultimate application of biotechnology use: Environment;Fewer than 250 employees;13
%Company by field(s) of ultimate application of biotechnology use: Environment;250 or more employees;17
%Company by field(s) of ultimate application of biotechnology use: Environment;Total;14
%Company by field(s) of ultimate application of biotechnology use: Industry;Fewer than 250 employees;13
%Company by field(s) of ultimate application of biotechnology use: Industry;250 or more employees;9
%Company by field(s) of ultimate application of biotechnology use: Industry;Total;12
Personnel in R&D in biotechnology (no. of persons);Fewer than 250 employees;8.124
Personnel in R&D in biotechnology (no. of persons);250 or more employees;3.386
Personnel in R&D in biotechnology (no. of persons);Total;11.510
Personnel in R&D in biotechnology (no. of persons): Researchers;Fewer than 250 employees;4.552
Personnel in R&D in biotechnology (no. of persons): Researchers;250 or more employees;1.650
Personnel in R&D in biotechnology (no. of persons): Researchers;Total;6.202
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;Fewer than 250 employees;3.572
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;250 or more employees;1.736
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;Total;5.308
Personnel in R&D in biotechnology (no. of persons): women;Fewer than 250 employees;4.363
Personnel in R&D in biotechnology (no. of persons): women;250 or more employees;2.026
Personnel in R&D in biotechnology (no. of persons): women;Total;6.389
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;Fewer than 250 employees;2.368
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;250 or more employees;935
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;Total;3.304
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;Fewer than 250 employees;1.995
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;250 or more employees;1.090
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;Total;3.086
Personnel in R&D in biotechnology (FTE);Fewer than 250 employees;5.788,1
Personnel in R&D in biotechnology (FTE);250 or more employees;2.448,9
Personnel in R&D in biotechnology (FTE);Total;8.236,9
Personnel in R&D in biotechnology (FTE): Researchers;Fewer than 250 employees;3.364,3
Personnel in R&D in biotechnology (FTE): Researchers;250 or more employees;1.231,9
Personnel in R&D in biotechnology (FTE): Researchers;Total;4.596,1
Personnel in R&D in biotechnology (FTE): Technicians and assistants;Fewer than 250 employees;2.423,8
Personnel in R&D in biotechnology (FTE): Technicians and assistants;250 or more employees;1.217
Personnel in R&D in biotechnology (FTE): Technicians and assistants;Total;3.640,8
Personnel in R&D in biotechnology (FTE): women;Fewer than 250 employees;3.197,5
Personnel in R&D in biotechnology (FTE): women;250 or more employees;1.501
Personnel in R&D in biotechnology (FTE): women;Total;4.698,5
Personnel in R&D in biotechnology (FTE): (women) Researchers;Fewer than 250 employees;1.803,7
Personnel in R&D in biotechnology (FTE): (women) Researchers;250 or more employees;708,8
Personnel in R&D in biotechnology (FTE): (women) Researchers;Total;2.512,5
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;Fewer than 250 employees;1.393,8
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;250 or more employees;792,2
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;Total;2.186
Internal expenditure on R&D (thousands of euros);Fewer than 250 employees;558.184
Internal expenditure on R&D (thousands of euros);250 or more employees;211.247
Internal expenditure on R&D (thousands of euros);Total;769.431
1) By nature of the expense: Current expenses;Fewer than 250 employees;518.032
1) By nature of the expense: Current expenses;250 or more employees;201.684
1) By nature of the expense: Current expenses;Total;719.715
1.1) Remuneration to researchers;Fewer than 250 employees;154.555
1.1) Remuneration to researchers;250 or more employees;66.892
1.1) Remuneration to researchers;Total;221.447
1.2) Remuneration to technicians and assistants;Fewer than 250 employees;72.617
1.2) Remuneration to technicians and assistants;250 or more employees;50.192
1.2) Remuneration to technicians and assistants;Total;122.809
1.3) Other current expenses;Fewer than 250 employees;290.860
1.3) Other current expenses;250 or more employees;84.599
1.3) Other current expenses;Total;375.459
2) By nature of the expense: Capital expenses;Fewer than 250 employees;40.152
2) By nature of the expense: Capital expenses;250 or more employees;9.563
2) By nature of the expense: Capital expenses;Total;49.715
2.1) Land and buildings;Fewer than 250 employees;6.661
2.1) Land and buildings;250 or more employees;2.860
2.1) Land and buildings;Total;9.521
2.2) Equipment and instruments;Fewer than 250 employees;24.465
2.2) Equipment and instruments;250 or more employees;6.001
2.2) Equipment and instruments;Total;30.466
2.3) Acquisition of specific R&D software;Fewer than 250 employees;1.157
2.3) Acquisition of specific R&D software;250 or more employees;653
2.3) Acquisition of specific R&D software;Total;1.810
2.4) Otros productos de propiedad intelectual específicos para I+D;Fewer than 250 employees;7.869
2.4) Otros productos de propiedad intelectual específicos para I+D;250 or more employees;49
2.4) Otros productos de propiedad intelectual específicos para I+D;Total;7.919
1.1) By origin of the funds: Own funds;Fewer than 250 employees;385.847
1.1) By origin of the funds: Own funds;250 or more employees;105.066
1.1) By origin of the funds: Own funds;Total;490.913
1.2) By origin of the funds: From companies;Fewer than 250 employees;53.140
1.2) By origin of the funds: From companies;250 or more employees;29.409
1.2) By origin of the funds: From companies;Total;82.548
1.3) By origin of the funds: Public Administration funds;Fewer than 250 employees;64.168
1.3) By origin of the funds: Public Administration funds;250 or more employees;32.641
1.3) By origin of the funds: Public Administration funds;Total;96.809
1.4) By origin of the funds: From Universities;Fewer than 250 employees;197
1.4) By origin of the funds: From Universities;250 or more employees;0
1.4) By origin of the funds: From Universities;Total;197
1.5) By origin of the funds: From non profit private institutions;Fewer than 250 employees;588
1.5) By origin of the funds: From non profit private institutions;250 or more employees;4.177
1.5) By origin of the funds: From non profit private institutions;Total;4.766
1.6) By origin of the funds: Foreign funds;Fewer than 250 employees;54.244
1.6) By origin of the funds: Foreign funds;250 or more employees;39.954
1.6) By origin of the funds: Foreign funds;Total;94.197
Purchase of R&D services in biotechnology (thousands of euros);Fewer than 250 employees;68.331
Purchase of R&D services in biotechnology (thousands of euros);250 or more employees;51.951
Purchase of R&D services in biotechnology (thousands of euros);Total;120.281
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Fewer than 250 employees;22.667
Purchase of R&D services in biotechnology (thousands of euros): In Spain;250 or more employees;46.897
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Total;69.564
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Fewer than 250 employees;45.664
Purchase of R&D services in biotechnology (thousands of euros): Abroad;250 or more employees;5.054
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Total;50.718
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Fewer than 250 employees;47
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;250 or more employees;23
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Total;45
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Fewer than 250 employees;12
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;250 or more employees;13
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Total;12
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Fewer than 250 employees;16
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;250 or more employees;15
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Total;16
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Fewer than 250 employees;13
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;250 or more employees;15
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Total;14
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Fewer than 250 employees;17
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;250 or more employees;11
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Total;16
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Fewer than 250 employees;19
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;250 or more employees;10
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Total;18
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Fewer than 250 employees;16
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;250 or more employees;13
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Total;15
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Fewer than 250 employees;37
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;250 or more employees;29
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Total;37
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Fewer than 250 employees;53
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;250 or more employees;39
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Total;52
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Fewer than 250 employees;20
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;250 or more employees;14
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Total;20
% Companies that have requested biotechnology patents in Biotechnology;Fewer than 250 employees;15
% Companies that have requested biotechnology patents in Biotechnology;250 or more employees;17
% Companies that have requested biotechnology patents in Biotechnology;Total;15
Number of patents requested;Fewer than 250 employees;525
Number of patents requested;250 or more employees;156
Number of patents requested;Total;681
% Companies with income of an international origin related to biotechnological activities;Fewer than 250 employees;24,9
% Companies with income of an international origin related to biotechnological activities;250 or more employees;18,4
% Companies with income of an international origin related to biotechnological activities;Total;24,3
% Turnover representing income of an international origin related to biotechnological activities;Fewer than 250 employees;6
% Turnover representing income of an international origin related to biotechnological activities;250 or more employees;1
% Turnover representing income of an international origin related to biotechnological activities;Total;1
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Fewer than 250 employees;45,2
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;250 or more employees;73,1
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Total;59,6
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Fewer than 250 employees;54,8
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;250 or more employees;26,9
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Total;40,4
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Fewer than 250 employees;89
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;250 or more employees;72,5
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Total;80,4
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Fewer than 250 employees;7,5
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;250 or more employees;24,9
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Total;16,5
% Income of an international origin related with activities according to the classification: Operating source abroad;Fewer than 250 employees;2,2
% Income of an international origin related with activities according to the classification: Operating source abroad;250 or more employees;2,3
% Income of an international origin related with activities according to the classification: Operating source abroad;Total;2,2
% Income of an international origin related with activities according to the classification: Other;Fewer than 250 employees;1,4
% Income of an international origin related with activities according to the classification: Other;250 or more employees;0,4
% Income of an international origin related with activities according to the classification: Other;Total;0,9